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Abstract TheapolipoproteinE(APOE)genotypeisagenetic
risk factor for dementia, Alzheimer’s disease, and cardiovas-
cular disease (CVD). It includes three alleles (e2, e3, e4) that
are located on chromosome 19q3.2. The e3 allele is the most
commonandismorecommoninpeopleofNorthernEuropean
ancestry and less common in those of Asian ancestry. Those
with at least one e4 allele are at increased risk for CVD
outcomes.Itiswellestablishedthatthepresenceofane4allele
is linked to higher low-density lipoprotein cholesterol levels,
even at young ages. Even though most CVD occurs in older
people, there are few studies of the effects of APOE on CVD
in older people. This review addresses recent research on the
links between APOE, CVD, and vascular mechanisms by
which APOE may affect CVD in the elderly.
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Introduction
In 2006, cardiovascular diseases (CVD) accounted for
34.3% of all deaths in the United States [1] (approximately
the deaths of 831,000 people). In that year, there were an
estimated 74 million people with high blood pressure,
nearly 18 million with coronary heart disease (CHD), and
6.4 million with strokes. The vast majority of these events
and diagnoses occur among people aged ≥65 years, such
that the prevalence of heart disease and stroke in people
over 65 years of age is nearly four times higher compared
with people aged 18 to 64 years [2]. Personal health care
expenditures in 2005 for Medicare recipients for heart
disease, stroke, and hypertension totaled nearly $50,000 per
person [3]. According to statistics published by the
National Center for Health Statistics, the prevalence of
these conditions in the United States in people aged
≥65 years declined by about 20% between1999 and 2006.
However, it is likely that death from CVD in people with
these conditions is simply being postponed, and that the
decline in the death rates will lead to a potential future
increase in CVD morbidity in people over the age of
80 years [1] because those who would have died instead
survive with their condition and contribute to the overall
population burden of CVD-related chronic conditions [1].
Treatments for CVD and prevention of risk factors for CVD
have become more effective and more widely used. Statin
drugs were used by 24 million Americans in 2003 and 2004
and their use is higher among people with higher levels of
low-density lipoprotein cholesterol (LDL-C) who are aged
≥75 years than among those aged 20 to 39 years [4].
Cigarette smoking is a prime example of this kind of
change, as prevalence of smoking has declined and in 2006
to 2008, 23% of those over age 18 years were current
smokers compared with nearly 40% of those over 65 years
of age.
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DOI 10.1007/s12170-010-0118-4Studies of coronary heart disease, lipids, and coronary atherosclerosis from 2000 to 2010
Study Year Cases/sample
or controls
Age
range, y
Ethnic group Design APOE allele Outcome Risk estimate
(95% CI)
Slooter
et al. [20]
2004 185/6852 55+ Europeans Cohort e3/e4 or e4/e4 MI 1.0 (0.7–1.4)
1.7 (0.8–3.6)
Ward
et al. [21￿]
2009 2712/22,169 40–79 Europeans Cohort Any e4
a CHD 1.09 (1.0–1.19)
Scuteri
[11]
2001 104/730 21–96 US white men Cohort Any e4
a Coronary events 2.01 (1.4–3.1)
Volcik
et al. [19]
2006 447/12,491 45–64 US whites and blacks Cohort Any e4
a CHD Whites: 1.07 (0.94–1.21)
Blacks: 1.13 (0.91–1.40)
Lahoz
et al. [42]
2001 242/1668 11–65 US white men Cohort Any e4
a CVD 1.46 (0.99–2.15)
Lahoz
et al. [42]
2001 121/1739 9–62 US white women Cohort Any e4
a CHD 1.36 (0.78–2.38)
Bennett
et al. [16]
2007 37,850/82,727
c NA Mixed studies Meta-analysis of 121
case-control studies
with 500+
Any e4
a CHD 1.06 (0.99–1.13)
Song
et al. [13]
2004 15,492/32,965 NA Mixed studies Meta-analysis of 48
case-control studies
Any e4
a CHD 1.42 (1.26–1.61)
Anand
et al. [14]
2009 25,348/51,484 30–64 Asian, European,
Arab, Nepalese
Case control e4
a MI 1.07 (1.01–1.28)
Keavney
et al. [15]
2004 4685/3420 30–64 UK whites Case control Per e4 allele
vs e2/e3
Nonfatal MI 1.16 (1.06–1.27)
Georgoulias
et al. [22]
2009 410 40–87 Greek Patient group Any e4
a Myocardial
perfusion SSS > 2
b
35.8 (13.1–98.1)
Frikke-Schmidt
et al. [43]
2000 940/9241 20–80 Danish men Case-referent e4/e3
a IHD 1.16 (0.96–1.41)
Liu
et al. [17]
2003 385/373 40–84 US men Nested case control Any e4
a MI 0.93 (0.63–1.37)
Mooijaart
et al. [18]
2006 546 85 Dutch Cohort e4/e3
modified by
plasma APOE
Cardiovascular
death
Intermediate plasma
APOE: 2.81
c (1.02–7.74)
High plasma
APOE: 4.25
c (1.38–13.0)
APOE apolipoprotein E; CHD coronary heart disease; CVD cardiovascular disease; IHD ischemic heart disease; MI myocardial infarction; SSS
summed stress score; UK United Kingdom; US United States
aVersus e33
bSeverity of perfusion defect under stress
cIntermediate and high plasma ApoE
Studies of stroke, hypertension, and carotid atherosclerosis from 2000 to 2010
Study Year Cases/sample
or controls
Age
range, y
Ethnic group Design APOE Outcome Risk estimate
(95% CI)
McCarron
et al. [44]
1999 9 studies NA Japanese, Canadian,
European
Meta-analysis of 9
case-control studies
Any e4
+ Ischemic CVD 1.68 (1.36–2.09)
Slooter
et al. [20]
2004 149/6852 55 + Dutch Cohort e3/e4 e4/e4 Ischemic stroke 0.9 (0.6–1.3)
0.6 (0.1–2.5)
van Vliet
et al. [34]
2007 99/561 85+ Dutch Cohort e3/e4
+ Stroke 3.01 (1.34–6.74)
Wang
et al. [45￿]
2009 396/396 57 (mean) Han Chinese Case control Any e4
+ Stroke 1.50 (1.13–1.91)
Sturgeon
et al. [46]
2007 180/5054 45–64 US white men Cohort Any e4
+ Ischemic stroke 0.98 (0.70–1.38)
Sturgeon
et al. [46]
2007 97/1499 45–64 US black men Cohort Any e4
+ Ischemic stroke 0.77 (0.49–1.24)
Banerjee
et al. [47]
2007 6107 50–70 Asian Meta-analysis Any e4
+ Stroke 1.47 (1.00, 2.15)
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factor for dementia, Alzheimer’s disease, and CVD. It is
among the more common genotypes. It includes 3 alleles
(e2, e3, e4) and 6 genotypes (e22, e23, e24, e33, e34,
e44) that occur on chromosome 19q3.2. The e3 allele is
t h em o s tc o m m o no ft h et h r e ea n dm a yb ec o n s i d e r e d
an ancestral allele. The e4 allele is more common in
people of Northern European ancestry and lower in
those of Asian ancestry [5]. Those with at least one e4
allele are at increased risk for CVD outcomes, and
homozygosity for e4 (ie, e4/e4) increases risk further. It
is well established that the presence of an e4 allele is
linked to higher LDL-C levels; this is found even at
younger ages, and LDL-C increases more rapidly with age
in those with the e4 allele [6].
Apolipoprotein E is often found to interact with
environmental risk factors, such as smoking or diet, to
increase risk. Compared with e2 or e3, the e4 allele may
contribute to earlier and higher mortality, which in turn
contributes to a lower occurrence of the e4 allele in older
compared with younger people [7–9]. Apolipoprotein E is
often reported to modify the effects of environmental risk
factors such as diet, smoking, or physical activity on
cardiovascular outcomes.
Multiple individual studies, reviews, and meta-
analyses have previously examined and summarized the
influence of the APOE genotype on the risk of CVD.
Most studies have focused on CHD, atherosclerosis,
hypertension, and ischemic stroke, and some mechanis-
tic studies have evaluated the role of lipids and
inflammation in the links between apolipoprotein e4
and vascular outcomes. This review includes only
studies published after 1998 that were sufficiently large
to have statistically significant effects. In addition, only
studies for which the referent or target population was
identifiable were selected. This review is divided into
studies examining 1) cerebrovascular diseases, including
ischemic stroke, hypertension, or carotid atherosclerosis;
and 2) studies examining CHD, lipids, and coronary
atherosclerosis. Only studies in which there were older
adults were included, with the exception of a longitu-
dinal study of young adults modeling change over time
i nL D L - Ci nr e l a t i o nt oa p o l i p o p r o t e i nE[ 6]. Only a few
studies that are restricted to older populations (age
≥65 years) have been done of the effects of apolipoprotein
E on these outcomes. Most studies include middle-aged
individuals with smaller numbers of older individuals, and
they do not report apolipoprotein E effects by age strata or
test interactions between apolipoprotein E and age.
Therefore, information about the differences between
younger and older people in the effects of apolipoprotein
E on vascular outcomes is limited. The effects of
population heterogeneity by nationality, race, or ethnicity
on apolipoprotein E and vascular outcomes is addressed in
a number of recent studies.
Stroke
Ischemic stroke is the most common form of stroke and the
most frequent stroke outcome studied in relation to
apolipoprotein e4. Three of the publications included here
did not distinguish ischemic from hemorrhagic stroke.
Overall, the risk of ischemic stroke in those with an e4
compared with an e3 allele ranges from a risk of 0.77 (95%
CI, 0.49–1.24) in US middle-aged black men [46] to 3.01
(95% CI, 1.34–6.74) in Dutch people over the age of
85 years [34]. Among studies of people of Asian origin, the
elevated risk of stroke associated with apolipoprotein e4 is
more consistent (around 1.50 for e4 vs e3) than in people of
European origin, in whom it ranges from 0.90 to 1.68 in
samples of middle-aged individuals [20, 44].
Hypertension and carotid atherosclerosis are common
mechanisms related to stroke risk. Only one recent study has
examined the association between apolipoprotein e4 and
hypertension [10], yielding a risk of 1.97 (95% CI, 1.11–
3.52) in a meta-analysis of six cohort studies of Asians [46].
In addition, four studies in various population groups have
reported significant increases in carotid atherosclerosis or
carotid plaques in those with an e4 compared with an e3
Lahoz
et al. [42]
2001 242/1668 11–65 US white men Cohort Any e4
+ CVD 1.46 (0.99–2.15)
Niu
et al. [10]
2009 1812/1762 40+ Asian Meta-analysis of 6
case-control studies
Any e4
+ Hypertension 1.97 (1.11–3.52)
Volcik
et al. [19]
2006 15,792 45–64 US white and black Cohort Any e4
+ Carotid IMT (mean [SE])
a e4: 0.74 (0.003)
Debette
et al. [48]
2006 5856 65+ European Cohort e4/e4 vs. e33 Carotid plaque 2.12 (1.27–3.53)
Beilby
et al. [49]
2003 1109 27–77 Australian white men Cross-sectional e4/e4 e3/e4 Carotid plaque 2.85 (0.49–16.6)
1.79 (1.01–3.17)
APOE apolipoprotein E; CVD cardiovascular disease; IMT intimal media thickness
aP<0.05 versus e33
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cerebrovascular disease that we reviewed, only four were
restricted to people over the age of 55 years and none ex-
amined age-specific effects or tested interactions between
apolipoprotein E and age [20, 34, 47, 48].
Notable among these studies are the following. 1) The
only study to focus on elderly people (age ≥85 years) found
that the effects of the e3/e3 and e3/e4 genotypes on
stroke were mediated by plasma apolipoprotein E levels
[34]. In e3/e4 carriers, a 1-SD difference in plasma
apolipoprotein E was associated with a threefold increase
in stroke risk (P=0.002). In the e3/e3 genotype, this risk
was 1.95 (P=0.002). Stroke risk in e2 carriers was not
mediated by plasma apolipoprotein E. 2) A meta-analysis
of six studies of hypertension risk including only Asian
participants that compared the e3 to the e4 allele found
that the odds of hypertension were elevated in e4 carriers
[47]. The summary estimate was more consistent than
studies of Europeans. It is possible that there is less
subpopulation heterogeneity in this group of Asian studies
than in European studies.
Coronary Heart Disease
In the current literature, several large cohort studies report
that the apolipoprotein e4 allele is associated with an
increased risk of CHD, with a risk ranging between 1.1 and
2.0 [11–16]. Six of the 13 found a significantly increased
risk of CHD in e4 carriers. Three of the 13 studies found no
association between the e4 allele and CHD [17–19].
Mooijaart et al.’s study [18] was the only population-
based study we found that restricted enrollment to elderly
participants who were Dutch and ≥85 years of age. Some of
these studies may have lacked power to detect differences
in CHD risk due to small sample size.
In a Dutch cohort study of 6852 men and women
55 years of age were followed for up to 8 years, the authors
reported that the e4 allele was weakly associated with
myocardial infarction, with e3/e4 individuals experiencing
no increased risk (RR=1.0; 95% CI, 0.7–1.4) compared
with e3/e3 individuals [20]. In the same study, e4/e4
individuals, who made up a small proportion of the sample
(n=162), experienced an increased risk that was not
statistically significant (relative risk=1.7; 95% CI, 0.8–3.6)
[20].
In a cohort study of 25,630 English men and women
aged 40 to 79 years who were followed for up to 11 years,
individuals with the e4 allele experienced a slightly higher
risk for CHD (hazard ratio=1.09; 95% CI, 1.0–1.19) [21￿].
This relation was mediated by the ratio of low-density
lipoprotein (LDL) to high-density lipoprotein (HDL); add-
ing this variable to the regression models changed the
hazard ratio to 1.06 (95% CI, 0.95–1.18), but the
association remained statistically significant.
A cohort study of 1094 Swedish men and women
75 years or older at baseline who were followed for up to
18 years found Individuals with the e4 allele were
significantly more likely to die than individuals who were
homozygous for the e3 allele over the 18 years of follow-up
(RR=1.22; 95% CI, 1.07–1.41) [9]. The authors investi-
gated whether this relation was modified by ischemic heart
disease or dementia. They found that increased risk of
mortality was mediated by dementia but not by ischemic
heart disease, but gender was an effect modifier.
A 2007 meta-analysis of 121 large studies found that
individuals with the e4 allele had a slightly higher risk of
CHD (odds ratio=1.06; 95% CI, 0.99–1.13) [16]. There are
very few large studies examining the role of apoe4 in
relation to coronary atherosclerosis. One study of patients
aged 61 years (mean) who underwent exercise-rest myo-
cardial perfusion single positron emission computed to-
mography (SPECT) reported that individuals who were
homozygous for e3 and e4 and individuals who were
heterozygous for e4 had significantly higher values of a
summed stress score (SSS) compared with those who were
heterozygous for the e3 allele (P<0.001) [22]. After
adjustment for demographic and clinical risk factors, both
APOE genotypes were independent predictors, with a
cumulative contribution for the prediction of SSS and
summed difference score. All APOE4 genotypes had higher
levels of abnormal SSS, indicating they are linked to
coronary atherosclerosis.
Cardiovascular Mechanisms
Lipids
Many studies have found that individuals with the
apolipoprotein e4 allele have higher plasma LDL levels
than individuals without the apolipoprotein e4 allele [16,
18, 19, 21￿, 23]. For example, work by Giltay et al. [23]
reported that LDL-C was significantly (P<0.001) lower in
those with the e2/e2 or the e3/e2 genotype (mean of
3.2 mmol/L [95% CI, 3.0–3.5]) than in those with the e3/4
(mean of 4.1 mmol/L [95% CI, 3.9–4.2]) or e4/e4 genotype
(mean of 4.5 mmol/L [95% CI, 3.9–5.2]). Similarly, high-
density lipoprotein cholesterol (HDL-C) was significantly
(P<0.001) higher in those with the e2/e2 (mean of
1.31 mmol/L [95% CI, 1.25–1.37 mmol/L]) and e3/e2
genotypes (mean of 1.24 mmol/L [95% CI, 1.14–1.34]) than
in those with the e4/e3 (mean of 1.20 [95% CI, 1.16–1.23])
or the e4/e4 (mean of 1.17 [95% CI, 1.01–1.34]) genotypes.
It is less clear whether this apolipoprotein-related increase
in LDL leads to an increased risk of CVD. Two recent cohort
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shipbetweenapolipoproteine4genotypesandCHD[15, 21￿].
However, three of these studies reported that the apolipo-
protein e4 allele is associated with significantly higher
plasma LDL levels but not associated with CHD. In a
2007 meta-analysis of 82 large case-control studies, e4/e3
individuals had 0.13 mmol/L (95% CI, 0.09–0.16) higher
mean plasma LDL levels than e3/e3 individuals [16], and in
a cohort of 22,279 European men aged 70 to 89 years at
baseline, e4 carriers had significantly higher plasma LDL
levels than non–e4 carriers (mean difference of 0.23 mmol/L
[95% CI, 0.09–0.37]) over 15 years of follow-up [24].
A Dutch cohort study enrolled 561 individuals aged
85 years and followed them for an average of 4.2 years [18].
On average, plasma LDL-C levels were significantly higher
in e4/e3 individuals than in e3/e3 individuals (4.14 mmol/L
[95% CI, 3.96–4.32] vs 3.70 mmol/L [95% CI, 3.60–3.80];
P<0.001). Over the course of the study, 68 participants died
of CVD. The authors reported that e4/e3 and e4/4 carriers
experienced a nonsignificant increased risk for cardiovascu-
lar mortality compared with e3/e3 individuals. The results of
this study suggest that in the elderly, higher plasma LDL
levels may not be associated with CVD. However, this study
may have lacked power to detect differences in cardiovas-
cular mortality due to smaller sample size.
A nested case-control study found significantly higher
mean plasma LDL levels in individuals with the e3 allele
compared withe3/e3 individuals(mean of 3.51 mmol/L [95%
CI, 3.37–3.65] and 3.64 mmol/L [95% CI, 3.56–3.72],
respectively), but the authors did not find an increased risk
of first myocardial infarction in e4 carriers compared with
e3/e3 individuals (odds ratio=0.87; 95% CI, 0.62–1.23) [17].
Change in Exposure to Lipids and Other CVD Risk Factors
with Age
Risk factors for CVD tend to change with aging due to
changes in lifestyle, selective survival, or age-dependent
physiologic changes. There are also cohort effects represent-
ing time-dependent changes in exposure to risk factors. As an
example, higher serum total cholesterol and LDL-C are well-
accepted as risk factors for CHD in middle age and early old
age,butthisassociationmaydisappearorreverseatolderages
[25]. Raiha et al. [25] reported in a cohort of 347 people
aged ≥65 years that elevated total serum cholesterol did not
predict vascular mortality but was a predictor of survival
from death due to nonvascular causes. In fact, lower lipid
levels were associated with poorer survival and higher with
better survival from vascular mortality, and the effects of
apolipoprotein e4 on death were unrelated to lipid levels.
Current lipid levels in the elderly do not accurately represent
lifetime exposure because many lifestyle factors (smoking,
heavy alcohol use) that influence lipids change with age and
these changes may modify lipid levels with advancing age
[26]. To the extent that APOE genotypes tend to interact with
vascular risk factors, changes in these risk factors can modify
risk. Smoking is lower in elderly populations compared with
youngergroups(21%vs9.3%in2008).Someofthismaybea
cohort effect, due to selective survival of nonsmokers or due
to smoking cessation. For these reasons, the impact of
apolipoprotein e4 on vascular outcomes may be attenuated
in elderly individuals if exposures vary by age and over time.
Thus,atolderages,thedeleteriouseffectsofapolipoproteine4
may not be exclusively mediated by dyslipidemia but also by
other mechanisms.
Inflammation
Considerable evidence now exists linking inflammatory
responses to an increased risk of CHD and stroke [27–30].
Inflammatory responses also increase in individuals with
chronic conditions, so inflammation is as likely to be a
marker of disease as a cause.
Inflammatory responses may be affected by the APOE
genotypes. C-reactive protein, which is variously linked to
CHD, varies by APOE genotype such that carriers of e2
and those with the e3/e3 genotype have higher levels of C-
reactive protein than those with e3/4 or e4/e4 [31, 32, 41].
In the very elderly (≥90 years of age), the e4 allele is linked
to a decreased C-reactive protein response compared with
younger people [33].
Fibrinogen, sometimes shown to be a CHD risk factor, is
higher in elderly people with e3/e4 versus e3/e3 or e4/e4.
Apolipoprotein e4 carriers have higher levels of the inflam-
matory cytokine interleukin (IL)-1β and lower levels of its
receptor antagonist. Tumor necrosis factor-α, and IL-6 are
downregulated by the e4 allele. Plasma apolipoprotein E in
very old people provokes an inflammatory response that may
be independent of the genotypes e4/e4 or e3/e4 [34].
Homocysteine is a sulfur amino acid that is variably linked
to stroke and to ischemic heart disease and sometimes to
dementia [35]. A recent meta-analysis suggested that homo-
cysteine is only a modest predictor of stroke and ischemic
heart disease. Although the presence of apolipoprotein e4
may be associated with higher risk of stroke and ischemic
heart disease, no studies have evaluated whether the
apolipoprotein e4 allele modifies the effects of homocysteine
on risk of stroke or of ischemic heart disease. Work by
Ravaglia et al. [36] in an elderly Italian cohort study found
that e4 carriers were less likely than noncarriers to have high
homocysteine and were also less likely to have high C-
reactive protein. The implications of these results for stroke or
ischemic heart disease risk are not clear; it may be that neither
homocysteine nor C-reactive protein are biochemical path-
ways by which APOE genotype influences the risk of stroke
or ischemic heart disease. It is also possible that selective
Curr Cardio Risk Rep (2010) 4:361–368 365survival mechanisms result in impaired immune response in
carriers of apolipoprotein e4 alleles in old age [32, 37].
Statins Use and APOE Genotype
Statin use has increasedrapidlyoverthe past 10 to15 years for
the purpose of lowering LDL-C levels and preventing CHD
and possibly stroke. Statins are highly effective in lowering
LDL-C and may also affect inflammation [38]. Although
apolipoprotein E is linked to LDL-C, relatively few studies
have been able to evaluate the effectiveness of statin therapy
in those with the e4 allele compared with the e3 or e2 allele.
A genome-wide association study was conducted on a sample
of 1984 men with a mean age of 62 years [39]. They were
enrolled in a randomized trial to test the effects of low-dose
versus high-dose statins on cardiovascular outcomes. This
trial evaluated 17 single nucleotide polymorphisms in relation
to LDL-C response to treatment over an 8-week period. Of
these, only APOE genotypes met study criteria; the least
LDL-C change occurred in those with an e4/4 genotype and
the largest change occurred in those with an e2/2 genotype. In
a series of patients with and without familial hypercholester-
olemia, the effects were tested of apolipoprotein E on lipid
response to either atorvastatin for those with familial hyper-
cholesteremia or to fenofibrate in those without familial
hypercholesteremia [40]. Among those with familial hyper-
cholesteremia, the largest change occurred in those with the
e2 allele (46-mg/dL decline) and the smallest change
occurred in carriers of the e4 allele (34.5-mg/dL decline;
comparison of baseline to post-treatment in both alleles was
P<0.0001). Among those without familial hypercholester-
emia, a similar pattern of change in LDL-C did not occur and
the results were similar for carriers of e2,e3 and e4 alleles.
Conclusions
Our summary of recent research on the effects of the APOE
genotypes on CVD in the elderly reveals a complex system
of relationships. APOE genotypes clearly influence lipids
and potentially inflammation, and may be linked to
atherosclerosis and hypertension. However, the association
of these biomarkers with CVD outcomes is altered in the
elderly, in part by age- and time-dependent changes in
exposure. The occurrence of APOE4 genotypes in older
populations has been seen to decline as well. From a
population perspective, this may mean that the fraction of
CVD cases attributable to apolipoprotein e4 may be smaller
and that the ability of e4 to influence CVD risk by
increasing LDL-C is more limited. There are few studies
of these issues in elderly people, and most of the research
includes middle-aged individuals. This age inclusion would
tend to attenuate the ability to observe age-specific effects.
The more recent research has provided some information
about subpopulation heterogeneity in the occurrence of e4
alleles and about related differences in effects on CVD. The
work by Niu et al. [10] is of particular value as it is one of
the only studies on e4 and hypertension in Asians.
The efficacy of active lipid-lowering interventions such
as statin use or diet on CVD may or may not be affected by
genetic risk factors such as apolipoprotein E. Most trials are
not designed to test whether the apolipoprotein genotypes
affect treatment efficacy. Given that in some populations e4
carriers comprise as much as 25% of the population, this is
an important omission. Clearly, more research is needed
that can help to elucidate the mechanisms by which
apolipoprotein E affects CVD in older populations.
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